The Biotech Tea
Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
Latest
Top
Discussions
Record-breaking M&As, dual-target IgAN drug, & slow-release semaglutide
No. 18 | July 9, 2026
Jul 9
•
Annicka Evans, PhD
4
1
XoFluza goes generic, methylation builds muscle, peptide panel raises flags
No. 17 | July 2, 2026
Jul 2
•
Annicka Evans, PhD
6
1
June 2026
mRNA flu shot era, CAR-T goes solid, $195M voucher cashed
No. 16 | June 25, 2026
Jun 25
•
Annicka Evans, PhD
3
8
Sound-powered gene delivery, bolus in a button, & a sunscreen upgrade
No. 15 | June 18, 2026
Jun 18
•
Annicka Evans, PhD
4
1
The CEO-to-Worker $ ratio, the measles playbook, & the wearable loophole
No. 14 | June 11, 2026
Jun 11
•
Annicka Evans, PhD
10
1
Standing ovation data, editing heart risk, & a tighter grant leash
No. 13 | June 4, 2026
Jun 4
•
Annicka Evans, PhD
8
1
May 2026
Enzymes without pigs, post-market food safety, & the "academic sleuth"
No. 12 | May 28, 2026
May 28
•
Annicka Evans, PhD
9
1
FDA Expedited Programs
A Few More Sips: A distilled comparison between Fast Track, Breakthrough, Accelerated, & Priority
May 25
•
Annicka Evans, PhD
4
1
The Ebola vaccine gap, reading vessel damage, & the Makary exit
No. 11 | May 21, 2026
May 21
•
Annicka Evans, PhD
12
6
Priority voucher tension, blood-based Alzheimer's detection, & FDA mini-inspections
No. 10 | May 14, 2026
May 14
•
Annicka Evans, PhD
4
4
"Jumping genes" for weight-loss, real-time trials, & the cost of misunderstood genetics
No. 9 | May 7, 2026
May 7
•
Annicka Evans, PhD
8
1
April 2026
$0 for restored hearing, the $100 genome, and the reimbursement gap
No. 8 | April 30, 2026
Apr 30
•
Annicka Evans, PhD
5
4
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
